Skip to Main Content

Paper Details

BRE12-158: A Postneoadjuvant, Randomized Phase II Trial of Personalized Therapy Versus Treatment of Physician's Choice for Patients With Residual Triple-Negative Breast Cancer.
J Clin Oncol
22
2022
BRE12-158, Capecitabine, Circulating tumor DNA, Patients, TNBC, Triple-Negative Breast Cancer, cancer, capecitabine, patients, triple-negative breast cancer, tumor, tumors
Author NameAffiliation
Guanglong JiangIndiana University Melvin and Bren Simon Comprehensive Cancer Center
Guanglong JiangIndiana University Melvin and Bren Simon Comprehensive Cancer Center
Rita NandaUniversity of Chicago
Claudine IsaacsGeorgetown University
Anna Maria StornioloIndiana University Melvin and Bren Simon Comprehensive Cancer Center
  • 1 - 5

Datasets

Release 1.2